Bringing the fundamentals into focus…
Back to TransMedics Group, Inc.
How TransMedics Group, Inc. stacks up
TMDX · against 380 other Healthcare companies of similar size
Valuation
70/ 100
Above the middle of the pack.
Ranked #120 of 381 · scores higher than 67% of peers
Bars: peers in each 10-point band of the valuation score35 peers with a valuation score of 70–79, including TMDX · Click a bar to see the companies
Why valuation scores 70?
Weighted metrics compared with all Healthcare companies.Mainly thanks to its earnings yield and free cash flow yield, which are stronger than most Healthcare peers.
- EBITDA yield is close to the peer norm. EBITDA yield: 4.2% vs peer median 4.0%
- more free cash flow for the price paid: stronger than 69% of peers. Free cash flow yield: 3.4% vs peer median 0.0%
- higher earnings for the price paid: stronger than 83% of peers. Earnings yield: 6.5% vs peer median 1.5%
Metric by metric
Position: dot = TMDX, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | TMDX | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 370 reported | 5.7% | 1.8% | 81% | 30% | |
| EBITDA yieldHigher is better · 378 reported | 4.2% | 4.3% | 49% | 50% | |
| Free cash flow yieldHigher is better · 192 reported | 3.4% | -0.3% | 68% | 20% | |
| Book yieldHigher is better · 370 reported | 22.2% | 32.8% | 33% | Context only |
Ranking by valuation score
Top 5 and the companies ranked around TMDXScores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score